DiA Imaging Analysis, an Israel-based healthcare technology company, has gained FDA clearance for LVivo IQS, software that uses artificial intelligence (AI) to improve the quality of images gathered during a cardiac ultrasound.

As the ultrasound is being performed, LVivo IQS scans the patient’s left ventricle, tracks the heart’s overall performance, and rates the quality of the image being acquired, using colors and numerical scoring that guide the user to higher quality images.

The software “helps ultrasound users overcome two major challenges in the field — scanning high-quality images and accurately analyzing them,” the company said.

The FDA cleared the software following a clinical study that showed that 91 percent of images saved using LVivo IQS were found to be clinically interpretable images.